Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Melanoma and other skin tumours

6257 - Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma


22 Oct 2018


Proffered paper session - Melanoma and other skin tumours


Targeted Therapy

Tumour Site



Georgina Long


G.V. Long1, A. Hauschild2, M. Santinami3, V.G. Atkinson4, M. Mandala5, V. Chiarion-Sileni6, J. Larkin7, C. Robert8, D. Schadendorf9, K. Dasgupta10, M. Shilkrut11, J. Garrett12, J.C. Brase13, R. Kefford14, J.M. Kirkwood15, R. Dummer16

Author affiliations

  • 1 Department Of Medical Oncology, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, 2060 - North Sydney/AU
  • 2 Department Of Dermatology, University Hospital Schleswig-Holstein, 24105 - Kiel/DE
  • 3 Melanomi E Sarcomi, Fondazione Istituto Nazionale Tumori, Milano/IT
  • 4 Division Of Cancer Services, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, 4102 - Queensland/AU
  • 5 Division Of Oncology, Papa Giovanni XXIII Cancer Center Hospital, 24127 - Bergamo/IT
  • 6 Melanoma Oncology Unit, Veneto Oncology Institute, Padova/IT
  • 7 Department Of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 8 Department Of Medicine, Institute Gustave Roussy, 94800 - Paris/FR
  • 9 Department Of Dermatology, University Hospital Essen, and German Cancer Consortium, 45122 - Essen/DE
  • 10 Biostatistics, Novartis Healthcare Pvt Ltd, Hyderabad/IN
  • 11 Oncology, Novartis Pharmaceuticals Corporation, 07936 - East Hanover/US
  • 12 Biostatistics, Novartis Pharmaceuticals Corporation, 07936 - East Hanover/US
  • 13 Biostatistics, Novartis Pharma AG, 4002 - Basel/CH
  • 14 Department Of Medical Oncology, Macquarie University, Melanoma Institute Australia, Westmead Hospital and University of Sydney, Sydney/AU
  • 15 Department Of Medicine, Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh/US
  • 16 Department Of Dermatology, University Hospital Zürich Skin Cancer Center, 8091 - Zurich/CH


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6257


Primary analysis of COMBI-AD (NCT01682083) showed significant improvement in RFS with adjuvant D + T vs placebo (Pbo; HR, 0.47; P < .001). We present an RFS analysis with extended follow-up (FU), a cure-rate model, and biomarker analysis.


COMBI-AD is a randomized, phase 3 trial evaluating 12 mo of adjuvant D + T vs Pbo in pts with resected BRAF V600–mutant stage III melanoma. A Weibull mixture cure-rate model was used to estimate the proportion of pts who will not relapse. Mutational landscape and gene expression signatures (GES) were examined in baseline tissue samples by sequencing 570 genes and gene expression profiling (GEP) with a NanoString® panel.


Median FU was 44 mo (D + T) and 42 mo (Pbo); 177/438 pts (41%) in the D + T arm and 254/432 pts (59%) in the Pbo arm had relapsed/died. Median RFS was not reached (NR; 95% CI, 46.9 mo-NR) with D + T vs 16.6 mo (95% CI, 12.7-22.1 mo) with Pbo (HR, 0.49 [95% CI, 0.40-0.59]). Estimated cure rate was 54% (95% CI, 49%-59%) with D + T vs 37% (95% CI, 32%-42%) with Pbo. DNA sequencing, GEP, and paired DNA + RNA results were available for 368, 507, and 301 pts, respectively. MAPK pathway gene alterations did not correlate with outcome. Immune GES (eg, interferon [IFN]-γ signature) were strongly prognostic in both arms. High tumor mutational burden (TMB) added positive prognostic value to IFN-γ signature in the Pbo arm (high IFN-γ and high TMB associated with longer RFS), whereas in the D + T arm, IFN-γ gene signature identified pts with longer RFS independently of TMB status. Exploratory analysis of RFS in D + T vs Pbo arms in all TMB/IFN-γ subgroups suggested that low TMB or high TMB/high IFN-γ may be associated with greater RFS benefit than high TMB/low IFN-γ.


The updated RFS and cure-rate model confirm the ongoing benefit of adjuvant D + T. MAPK gene alterations previously associated with targeted therapy resistance were not associated with outcome in the adjuvant setting. TMB and immune GES identified pts at higher risk of relapse in the Pbo arm. The predictive value of these markers with targeted therapy or checkpoint inhibitors warrants further validation in a prospective study.

Clinical trial identification


Editorial Acknowledgement

Medical writing assistance was provided by Michael Demars, PhD of ArticulateScience, LLC and funded by Novartis Pharmaceuticals Corporation

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.